- Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma2018 | First Faculty of Medicine
- Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma2021 | First Faculty of Medicine
- Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk2021 | First Faculty of Medicine
- Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma2021 | First Faculty of Medicine